Professor Andrew L. Hopkins elected Fellow of the Academy of Medical SciencesBusiness Wire • 05/17/23
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical StageBusiness Wire • 05/15/23
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of DirectorsBusiness Wire • 05/03/23
Data Presented at AACR 2023 Highlights Exscientia's Clinical and Preclinical DevelopmentBusiness Wire • 04/19/23
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACRBusiness Wire • 03/15/23
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine PlatformBusiness Wire • 03/07/23
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318Business Wire • 02/02/23
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual CongressBusiness Wire • 12/06/22
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid TumoursBusiness Wire • 11/28/22
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/15/22
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology TreatmentsBusiness Wire • 11/14/22
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022Business Wire • 11/08/22
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual SymposiumBusiness Wire • 10/26/22